Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Andrea VallsNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.
Cristina Ruiz-RoldánNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.ORCID 0009-0000-0900-1534
Jenita ImmanuelNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-7236-1855
Sonia Alonso-MartínCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science & Innovation, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-3254-0365
Eduard GallardoNeuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Roberto Fernández-TorrónNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.
Mario BonillaStem Cells and Aging Group, Bioengineering Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.
Ana LersundiDepartment of Traumatology, Donostialdea Integrated Health Organisation, Osakidetza, 20014 San Sebastian, Spain.
Aurelio Hernández-LaínDepartment of Neuropathology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Cristina Domínguez-GonzálezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Spanish Ministry of Science & Innovation, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0001-5151-988X
Juan Jesús VílchezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Spanish Ministry of Science & Innovation, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0002-0532-2872
Pablo IruzubietaCenter for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science & Innovation, Carlos III Health Institute, 28029 Madrid, Spain.ORCID 0000-0003-0331-6222
Adolfo López de MunainNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-9509-4032
Amets SáenzNeuromuscular Diseases Group, Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.ORCID 0000-0002-0704-1150
Funding
Association Française contre les Myopathies AFM 24743Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED CB06/05/1126Department of Health of the Government of the Basque Country 2021111022GENE-Association of Neuromuscular diseases of Gipuzkoa XInstituto de Salud Carlos III PI21/00047
6 · The paper itself
Abstract
Limb-girdle muscular dystrophy R1 (LGMDR1) is characterized by progressive proximal muscle weakness due to mutations in the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Role of Integrin β1D Mislocalization in the Pathophysiology of Calpain 3-Related Limb-Girdle Muscular Dystrophy. · full record | OpenQuestion